肺癌患者空腹血糖特点的回顾性临床研究

目的探讨肺癌患者与空腹血糖（FBG）的关系。方法选择入院前未经治疗、无糖尿病史的肺癌患者560例为研究组,根据细胞学类型分为2个亚组：小细胞肺癌组（70例）及非小细胞肺癌组（490例）。非小细胞肺癌组再根据病理分型分为鳞癌组（156例）、腺癌组（292例）和腺鳞癌组（42例）。另选取同期住院治疗的无糖尿病史的非恶性肿瘤患者500例为对照组。所有患者晨起采集空腹静脉血2 m L,采用葡萄糖氧化酶法进行FBG测定。对各组的FBG进行比较。结果除鳞癌组外,研究组及各亚组患者FBG明显高于对照组（均P〈0.05）。研究组、小细胞癌组、非小细胞肺癌组、腺癌组及腺鳞癌组6.1 mmol·L^-1〈FBG≤7．0mmol·L^-1。发生率高于对照组（P〈0．05）；研究组、小细胞肺癌组患者3．9mmol·L^-1≤FBG≤6．1mmol·L^-1发生率低于对照组（P〈0．05）。研究组各亚组患者的FBG比较差异均无统计学意义（均P〉0．05）。结论肺癌患者特别是小细胞癌、腺癌及腺鳞癌患者较容易发生FBG升高．且考虑与肺癌本身有关。

A Retrospective Clinical Study of Characteristics of Fasting Plasma Glucose in Lung Cancer Patients

Objective To explore the relationship between lung cancer and fasting blood glucose（FBG）. Methods A total of 560 patients with lung cancer who received no treatment before admission to hospital and had no history of diabetes were selected as the case group. These patients were further divided into two groups： small cell lung cancer group（n=70） and non-small cell lung cancer group（n=490）.Moreover, these patients with non-small cell lung cancer were further divided into three groups：squamous carcinoma group（n=156）, adenocarcinoma group（n=292） and adenosquamous carcinoma group（n=42）.In addition, 500 non-malignant tumor patients with a history of diabetes who received treatment during the same period were enrolled as the control group. Fasting venous blood samples（2 m L） were collected and FBG levels were determined by glucose oxidase method. Results Compared with control group, the levels of FBG and the incidence of 6.1 mmol·L^-1FBG≤7.0 mmol·L^-1significantly increased in small cell lung cancer group, adenocarcinoma group and adenosquamous carcinoma group, but the incidence of 3.9 mmol·L^-1≤FBG≤6.1 mmol·L^-1obviously decreased in small cell lung cancer group（all P〈0.05）. There were no significant differences in FBG levels between small cell lung cancer group and non-small cell lung cancer group, as well as among squamous carcinoma group, adenocarcinoma group and adenosquamous carcinoma group（P〉0.05）. Conclusion FBG levels often increase in patients with lung cancer, especially in patients with small cell lung cancer, adenocarcinoma or adenosquamous carcinoma. There is a correlation between FBG levels and lung cancer.